PMC:6640909 / 38075-39776 JSONTXT

{"project":"TEST0","denotations":[{"id":"31100109-227-234-7361","span":{"begin":619,"end":622},"obj":"[\"24239003\"]"},{"id":"31100109-234-241-7362","span":{"begin":1244,"end":1247},"obj":"[\"20639306\"]"},{"id":"31100109-218-225-7363","span":{"begin":1482,"end":1485},"obj":"[\"29402604\"]"}],"text":"Recommendations for the use of anticoagulation during LT-MCS\nRecommendations Class Level References\nManagement of anticoagulation preoperative, perioperative and postoperative of LT-MCS implantation\nIf intraoperative extracorporeal life support or off-pump implantation is performed, administration of a reduced dose of heparin may be considered. IIb C\nEarly postoperative anticoagulation starting with intravenous anticoagulation, followed by vitamin K antagonists, is recommended. I C\nThe use of low-molecular-weight heparin as an early postoperative anticoagulation regimen should be considered. IIa C [341]\nA postoperative international normalized ratio target between 2.0 and 3.0 is recommended. I C\nThe use of acetylsalicylic acid is recommended. I C\nThe use of low-molecular-weight heparin for bridging during long-term support is recommended. I C\nRe-evaluation of antithrombotic therapy during bleeding episodes is recommended. I C\nThe use of novel oral anticoagulants is not recommended. III B [342]\nManagement of anticoagulation in the event of bleeding episodes\nFor a major bleeding event, discontinuation of anticoagulation and reversal with blood components and coagulation factors are recommended. I C [343]\nFor minor bleeding, if the INR is above the therapeutic range, adjustment of anticoagulation agents should be considered. IIa C\nIn all cases of bleeding, exploration and treatment of a bleeding site should be considered. IIa C [344]\nAfter resolution of the first bleeding episode, discontinuation of long-term acetylsalicylic acid should be considered. IIa C\nINR: international normalized ratio; LT-MCS: long-term mechanical circulatory support."}

{"project":"MyTest","denotations":[{"id":"31100109-24239003-28905421","span":{"begin":619,"end":622},"obj":"24239003"},{"id":"31100109-20639306-28905422","span":{"begin":1244,"end":1247},"obj":"20639306"},{"id":"31100109-29402604-28905423","span":{"begin":1482,"end":1485},"obj":"29402604"}],"namespaces":[{"prefix":"_base","uri":"https://www.uniprot.org/uniprot/testbase"},{"prefix":"UniProtKB","uri":"https://www.uniprot.org/uniprot/"},{"prefix":"uniprot","uri":"https://www.uniprot.org/uniprotkb/"}],"text":"Recommendations for the use of anticoagulation during LT-MCS\nRecommendations Class Level References\nManagement of anticoagulation preoperative, perioperative and postoperative of LT-MCS implantation\nIf intraoperative extracorporeal life support or off-pump implantation is performed, administration of a reduced dose of heparin may be considered. IIb C\nEarly postoperative anticoagulation starting with intravenous anticoagulation, followed by vitamin K antagonists, is recommended. I C\nThe use of low-molecular-weight heparin as an early postoperative anticoagulation regimen should be considered. IIa C [341]\nA postoperative international normalized ratio target between 2.0 and 3.0 is recommended. I C\nThe use of acetylsalicylic acid is recommended. I C\nThe use of low-molecular-weight heparin for bridging during long-term support is recommended. I C\nRe-evaluation of antithrombotic therapy during bleeding episodes is recommended. I C\nThe use of novel oral anticoagulants is not recommended. III B [342]\nManagement of anticoagulation in the event of bleeding episodes\nFor a major bleeding event, discontinuation of anticoagulation and reversal with blood components and coagulation factors are recommended. I C [343]\nFor minor bleeding, if the INR is above the therapeutic range, adjustment of anticoagulation agents should be considered. IIa C\nIn all cases of bleeding, exploration and treatment of a bleeding site should be considered. IIa C [344]\nAfter resolution of the first bleeding episode, discontinuation of long-term acetylsalicylic acid should be considered. IIa C\nINR: international normalized ratio; LT-MCS: long-term mechanical circulatory support."}

{"project":"0_colil","denotations":[{"id":"31100109-24239003-7361","span":{"begin":619,"end":622},"obj":"24239003"},{"id":"31100109-20639306-7362","span":{"begin":1244,"end":1247},"obj":"20639306"},{"id":"31100109-29402604-7363","span":{"begin":1482,"end":1485},"obj":"29402604"}],"text":"Recommendations for the use of anticoagulation during LT-MCS\nRecommendations Class Level References\nManagement of anticoagulation preoperative, perioperative and postoperative of LT-MCS implantation\nIf intraoperative extracorporeal life support or off-pump implantation is performed, administration of a reduced dose of heparin may be considered. IIb C\nEarly postoperative anticoagulation starting with intravenous anticoagulation, followed by vitamin K antagonists, is recommended. I C\nThe use of low-molecular-weight heparin as an early postoperative anticoagulation regimen should be considered. IIa C [341]\nA postoperative international normalized ratio target between 2.0 and 3.0 is recommended. I C\nThe use of acetylsalicylic acid is recommended. I C\nThe use of low-molecular-weight heparin for bridging during long-term support is recommended. I C\nRe-evaluation of antithrombotic therapy during bleeding episodes is recommended. I C\nThe use of novel oral anticoagulants is not recommended. III B [342]\nManagement of anticoagulation in the event of bleeding episodes\nFor a major bleeding event, discontinuation of anticoagulation and reversal with blood components and coagulation factors are recommended. I C [343]\nFor minor bleeding, if the INR is above the therapeutic range, adjustment of anticoagulation agents should be considered. IIa C\nIn all cases of bleeding, exploration and treatment of a bleeding site should be considered. IIa C [344]\nAfter resolution of the first bleeding episode, discontinuation of long-term acetylsalicylic acid should be considered. IIa C\nINR: international normalized ratio; LT-MCS: long-term mechanical circulatory support."}

{"project":"2_test","denotations":[{"id":"31100109-24239003-28905421","span":{"begin":619,"end":622},"obj":"24239003"},{"id":"31100109-20639306-28905422","span":{"begin":1244,"end":1247},"obj":"20639306"},{"id":"31100109-29402604-28905423","span":{"begin":1482,"end":1485},"obj":"29402604"}],"text":"Recommendations for the use of anticoagulation during LT-MCS\nRecommendations Class Level References\nManagement of anticoagulation preoperative, perioperative and postoperative of LT-MCS implantation\nIf intraoperative extracorporeal life support or off-pump implantation is performed, administration of a reduced dose of heparin may be considered. IIb C\nEarly postoperative anticoagulation starting with intravenous anticoagulation, followed by vitamin K antagonists, is recommended. I C\nThe use of low-molecular-weight heparin as an early postoperative anticoagulation regimen should be considered. IIa C [341]\nA postoperative international normalized ratio target between 2.0 and 3.0 is recommended. I C\nThe use of acetylsalicylic acid is recommended. I C\nThe use of low-molecular-weight heparin for bridging during long-term support is recommended. I C\nRe-evaluation of antithrombotic therapy during bleeding episodes is recommended. I C\nThe use of novel oral anticoagulants is not recommended. III B [342]\nManagement of anticoagulation in the event of bleeding episodes\nFor a major bleeding event, discontinuation of anticoagulation and reversal with blood components and coagulation factors are recommended. I C [343]\nFor minor bleeding, if the INR is above the therapeutic range, adjustment of anticoagulation agents should be considered. IIa C\nIn all cases of bleeding, exploration and treatment of a bleeding site should be considered. IIa C [344]\nAfter resolution of the first bleeding episode, discontinuation of long-term acetylsalicylic acid should be considered. IIa C\nINR: international normalized ratio; LT-MCS: long-term mechanical circulatory support."}